Article Text

Download PDFPDF
Weekly topotecan in a heavily pretreated patient with peritoneal papillary serous adenocarcinoma*
  1. J. EVANS
  1. Cancer Care for Women, PC, Lancaster General Hospital, Lancaster, PA
  1. Address correspondence and reprint requests to: Jacque Evans, DO, Cancer Care for Women, PC, Department of Obstetrics and Gynecology, Lancaster General Hospital, 694 Good Drive, Suite 205, Lancaster, PA 17604-3444.


Peritoneal papillary serous adenocarcinoma is a rare müllerian tumor type that is histologically similar to ovarian serous carcinoma. The low incidence of peritoneal papillary serous adenocarcinoma has hindered the establishment of a standard of care for this disease. A 56-year-old woman, who had undergone an abdominal hysterectomy 25 years earlier, presented with a vaginal nodule and palpable pelvic mass. She underwent debulking surgery and was diagnosed with stage IIIC peritoneal papillary serous adenocarcinoma. After 6 cycles of paclitaxel/carboplatin and 10 cycles of liposomal doxorubicin/cyclophosphamide, laparotomy revealed microscopic disease. This heavily pretreated patient then started topotecan therapy (1.0 mg/m2/day, ×5 days). After several dosing adjustments because of fatigue and malaise, weekly topotecan 4.0 mg/m2 was determined to be the best-tolerated dosage. The patient ultimately received 14 weekly cycles of topotecan. After 12 weekly cycles, she achieved a complete response, which was maintained for 25 weeks with weekly topotecan therapy with a subsequent recurrence. Topotecan was reinstated. She maintains a disease-free interval of 58 weeks. Weekly topotecan demonstrated antitumor activity and was well tolerated in a patient with recurrent peritoneal papillary serous adenocarcinoma.

  • peritoneal papillary serous adenocarcinoma
  • topotecan
  • weekly

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.